52 related articles for article (PubMed ID: 24596533)
1. Engineered Cell-Derived Vesicles Displaying Targeting Peptide and Functionalized with Nanocarriers for Therapeutic microRNA Delivery to Triple-Negative Breast Cancer in Mice.
Bose RJ; Kumar US; Garcia-Marques F; Zeng Y; Habte F; McCarthy JR; Pitteri S; Massoud TF; Paulmurugan R
Adv Healthc Mater; 2022 Mar; 11(5):e2101387. PubMed ID: 34879180
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of urokinase plasminogen activator system in non-small cell lung cancer: A systematic review and meta-analysis.
Lu JJ; Guo H; Gao B; Zhang Y; Lin QL; Shi J; Liu JJ; Liu J
Mol Clin Oncol; 2018 Jan; 8(1):127-132. PubMed ID: 29387404
[TBL] [Abstract][Full Text] [Related]
3. Serum uPAR as Biomarker in Breast Cancer Recurrence: A Mathematical Model.
Hao W; Friedman A
PLoS One; 2016; 11(4):e0153508. PubMed ID: 27078836
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of urokinase plasminogen activator receptor in gastric and colorectal cancer: A systematic review and meta-analysis.
Guo H; Ling C; Ma YY; Zhou LX; Zhao L
Onco Targets Ther; 2015; 8():1503-9. PubMed ID: 26150727
[TBL] [Abstract][Full Text] [Related]
5. High concentration of urokinase-type plasminogen activator receptor in the serum of women with primary breast cancer.
Thielemann A; Baszczuk A; Kopczyński P; Kopczyński Z
Contemp Oncol (Pozn); 2013; 17(5):440-5. PubMed ID: 24596533
[TBL] [Abstract][Full Text] [Related]
6. Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
Gong SJ; Rha SY; Chung HC; Yoo NC; Roh JK; Yang WI; Lee KS; Min JS; Kim BS; Chung HC
Int J Mol Med; 2000 Sep; 6(3):301-5. PubMed ID: 10934293
[TBL] [Abstract][Full Text] [Related]
7. Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease.
Qin W; Zhu W; Wagner-Mann C; Sauter ER
Ann Surg Oncol; 2003 Oct; 10(8):948-53. PubMed ID: 14527916
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
9. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
Duggan C; Maguire T; McDermott E; O'Higgins N; Fennelly JJ; Duffy MJ
Int J Cancer; 1995 May; 61(5):597-600. PubMed ID: 7768629
[TBL] [Abstract][Full Text] [Related]
10. Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.
Andres SA; Edwards AB; Wittliff JL
J Clin Lab Anal; 2012 Feb; 26(2):93-103. PubMed ID: 22467324
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies in targeted therapy.
Powroźnik B; Kubowicz P; Pękala E
Postepy Hig Med Dosw (Online); 2012 Sep; 66():663-73. PubMed ID: 23001208
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of occult metastases in axillary sentinel lymph nodes of breast carcinoma.
Amir AS; Azar FP; Sahram N; Naser FM; Na'ma MR; Farid F; Khatoon AN; Ramin S; Ali TK
Pol J Pathol; 2012 Mar; 63(1):40-4. PubMed ID: 22535605
[TBL] [Abstract][Full Text] [Related]
13. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database.
Autier P; Boniol M; La Vecchia C; Vatten L; Gavin A; Héry C; Heanue M
BMJ; 2010 Aug; 341():c3620. PubMed ID: 20702548
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
